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Background: Krüppel-like factor 6 (KLF6) has been recently identified as a MEF2D target gene involved in neuronal
cell survival. In addition, KLF6 and TGFβ have been shown to regulate each other’s expression in non-myogenic cell
types. Since MEF2D and TGFβ also fulfill crucial roles in skeletal myogenesis, we wanted to identify whether KLF6
functions in a myogenic context.
Methods: KLF6 protein expression levels and promoter activity were analyzed using standard cellular and molecular
techniques in cell culture.
Results: We found that KLF6 and MEF2D are co-localized in the nuclei of mononucleated but not multinucleated
myogenic cells and, that the MEF2 cis element is a key component of the KLF6 promoter region. In addition, TGFβ
potently enhanced KLF6 protein levels and this effect was repressed by pharmacological inhibition of Smad3.
Interestingly, pharmacological inhibition of MEK/ERK (1/2) signaling resulted in re-activation of the differentiation
program in myoblasts treated with TGFβ, which is ordinarily repressed by TGFβ treatment. Conversely, MEK/ERK
(1/2) inhibition had no effect on TGFβ-induced KLF6 expression whereas Smad3 inhibition negated this effect,
together supporting the existence of two separable arms of TGFβ signaling in myogenic cells. Loss of function
analysis using siRNA-mediated KLF6 depletion resulted in enhanced myogenic differentiation whereas TGFβ
stimulation of myoblast proliferation was reduced in KLF6 depleted cells.
Conclusions: Collectively these data implicate KLF6 in myoblast proliferation and survival in response to TGFβ with
consequences for our understanding of muscle development and a variety of muscle pathologies.
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KLF6 is a member of the Krüppel-like Factors (KLF)
gene family which are a group of transcription factors
that contain three highly conserved Cys2-His2 type zinc
fingers located in the C-terminus [1,2]. Subsequently,
these proteins regulate a vast range of target genes by
preferentially binding to cognate GC-boxes or CACCC
elements. KLF6 was originally identified due to its ability
to regulate TATA-less gene promoters that can regulate* Correspondence: jmcderm@yorku.ca
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distribution, and reproduction in any mediumglycoproteins in placental cells [3]. Since then, KLF6 has
been found to be expressed in most tissues including
neuronal, hindgut, heart and limb buds [4] and is local-
ized in the nucleus [5]. Interestingly, homozygous null
KLF6 mice result in failure in the development of the
liver and yolk sac vasculature, resulting in early lethality
at (E)12.5 [4]. To date, the most well-established target
gene of KLF6 is Transforming growth factor β (TGFβ)
and its receptors [6], and subsequent studies have shown
a positive feedback loop by which TGFβ activation
enhances KLF6 transactivation properties through the for-
mation of a Smad3-Sp1-KLF6 protein complex [7]. TGFβ
and KLF6 cooperatively regulate a wide range of cellular
processes such as cell differentiation, proliferation andtral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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cently KLF6 was identified as a myocyte enhancer factor 2
(MEF2) target gene that is involved in neuronal cell sur-
vival [14]. Since TGFβ and MEF2 are two key regulators
of skeletal myogenesis and since KLF6 was identified in
the myogenic transcriptome [15], we wanted to investigate
the role of KLF6 in skeletal muscle cells.
Regulation of skeletal myogenesis is a complex process.
Initially paracrine factors instigate the migration of desig-
nated myotome progenitor cells to the dermomyotome re-
gion of the somite. These proliferating cells grow and
divide until cell contact triggers differential gene expression
and activation of the MEF2 proteins and muscle regulatory
factors (MRFs). This cascade of events causes morpho-
logical changes in the progenitor cells that allow them to
align and fuse to form multinucleated myotubes that can
eventually spontaneously contract as functional muscle fi-
bers. TGFβ antagonizes this process by preventing cells
from exiting the cell cycle hence maintaining myoblasts in
a proliferative state. TGFβ ligands bind to a type II receptor
which becomes activated and autophosphorylated [16]. The
activated type II receptor can then phosphorylate and acti-
vate a type I receptor, which in turn phosphorylates
receptor-mediated Smads(2/3) enabling them to dimerize
with Smad4 and translocate into the nucleus where they
can bind to other transcription factors and DNA, to repress
essential muscle genes and the expression of their down-
stream targets [17,18]. In addition, TGFβ also regulates the
mitogen-activated protein kinase (MAPK) pathway, which
involves a cascade of protein kinases (MAPKKK, MAPKK,
MAPK) that become activated in sequence by G-proteins
in response to TGFβ binding its receptors [19-21]. Upon
TGFβ activation, MEK1/2 (MAPKK) can phosphorylate
and activate Extracellular signal-regulated kinase (ERK)1/2
MAPK at conserved TEY sites, causing it to translocate
into the nucleus to regulate gene expression. These
two TGFβ-regulated pathways converge to inhibit the func-
tion of MEF2 and hence muscle-specific genes [22], and ul-
timately result in cell proliferation [23,24]. Not surprisingly,
inhibition of either or both of these pathways, (either
pharmacologically or through ectopically expressed Smad7,
which can antagonize the canonical Smad-pathway), en-
hances myotube formation [25,26]. Crosstalk between these
pathways is further supported by Smad7 antagonizing the
repressive effects of MEK1 on MyoD [26,27].
In this report, our goal was to assess the role of KLF6
in myogenic cells based on its regulation by both
MEF2D and TGFβ. We report that TGFβ upregulates
KLF6 specifically through a Smad3-dependent pathway,
which enhances proliferation in myoblasts. In addition,
we observed that 1) TGFβ enhanced KLF6 promoter ac-
tivation, and 2) that MEF2 is recruited to the KLF6 pro-
moter region but is not required for KLF6 activation by
TGFβ. Pharmacological inhibition of Smad3 repressedKLF6 expression by TGFβ and cell proliferation but, im-
portantly did not re-activate the differentiation program
which is potently repressed by TGFβ signaling. Con-
versely, TGFβ treatment coupled with pharmacological
inhibition of MEK1/2, enhanced myotube formation but
had no effect on KLF6 expression and function. Loss of
function assays using siRNA targeting KLF6 revealed
that KLF6 is required for cell proliferation. These experi-
ments tease apart two independent functions of TGFβ
signaling in myogenic cells. One is a repressive effect on
differentiation which is mediated by ERK activation, the
other being an enhancement of proliferation, which is
dependent on Smad3 and KLF6.
Methods
Plasmids
Expression plasmids for pcDNA3-MEF2D, pCMV β-
galactosidase [28,29], and reporter gene constructs for
3TP-lux [30], MCK-Luc [31], and MEF2-Luc [32] have
been previously described. KLF6 reporter constructs
pRMO6 and pROM6 ΔMEF2 were generously provided
by Dr. Nicolas P. Koritschoner (Faculty of Bioquimica y
Ciencias Biologicas, Universidad Nacional del Litoral,
Santa Fe, Argentina).
Antibodies
Anti-MEF2A rabbit polyclonal, anti-Myosin heavy chain
mouse monoclonal and anti-Myogenin mouse monoclonal
antibodies were produced with the assistance of the York
University (Toronto, Ontario, Canada) Animal Care Facility.
Anti-MEF2D (1:1000; BD Biosciences, Mississauga,
Ontario, Canada), Smad3, phospho-Smad3 and phospho-
ERK1/2 (1:1000; Cell Signaling, Toronto, Ontario,
Canada), and KLF6, actin, and ERK1/2 (1:1000; Santa
Cruz, Santa Cruz, CA95060, US) were used for immuno-
blotting experiments. Immunoglobulin G (IgG) was also
purchased from Santa Cruz Biotechnologies.
Cell culture, transfections and drug treatments
C2C12 cells were maintained in DMEM supplemented
with 10% fetal bovine serum (HyClone, Rockford, IL61101,
US), 1% L-glutamine and 1% penicillin-streptomycin. Cells
were maintained in a humidified, 37°C incubator with a 5%
CO2 atmosphere. For transfections, cells were seeded on
pre-gelatin-coated plates 1 day prior to transfection and
were transfected according to the standard calcium phos-
phate method previously described by Perry et al., 2001. A
mixture of 50 μl 2.5 M CaCl2 per 25 μg DNA with an equal
volume of 2× HeBS (2.8 M NaCl, 15 mM Na2HPO4, 50
mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
(HEPES), pH = 7.15) was used, and the cells were incubated
overnight followed by washing and addition of fresh media.
Drug treatments were used at the following concentrations:
2 ng/ml TGFβ, 5 μM Sis3 and 10 μM U0126 as indicated.
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siRNA targeting KLF6, MEF2D and non-specific scram-
ble RNA were purchased from Sigma. Transient trans-
fections were performed using TurboFect Transfection
Reagent (R0531, Fermentas) according to the manufac-
turer’s instructions. Turbofect (Fermentas): a 1:2 mixture
ratio of DNA to turbofect reagent (including 4 ng/ml
siRNA) in 200 μl serum-free DMEM was prepared for
19-h incubation.
Immunocytochemistry
C2C12 cells were treated as previously described by Salma
and McDermott, 2012 [14], and incubated overnight
with at 4°C with primary MEF2D and KLF6 antibodies
(1:100) diluted in 1.5% goat serum. Cells were washed
three times with PBS for 10 minutes and incubated with
the appropriate tetramethyl rhodamine iso-thiocyanate
(TRITC)/fluorescein isothiocyanate (FITC)-conjugated
secondary antibodies (1:500) in 1.5% goat serum (PBS)
for 2 h at room temperature (RT) following 4’,6-
diaminidino-2-phenylindole (DAPI) staining for 15 mi-
nutes at RT. Cells were washed three times with PBS
and cover slips were mounted with DAKO mounting
media (Dako) on glass slides. The fluorescence images
were captured using Fluoview 300 (Olympus).
Protein extractions, immunoblotting and reporter gene
assays
Cells were harvested using an NP-40 lysis buffer (0.5%
NP-40, 50 mM Tris–HCl (pH 8.0), 150 mM NaCl, 10 mM
sodium pyrophosphate, 1 mM ethylenediaminetetraacetic
acid (EDTA) (pH 8.0), 0.1 M NaF) containing 10 μg/ml
leupetin and aprotinin, 5 μg/ml pepstatin A, 0.2 mM
phenylmethylsulfonyl fluoride and 0.5 mM sodium
orthovanadate. Protein concentrations were determined
using the Bradford method (Bio-Rad) with BSA as a
standard. We used 20 μg of total protein extracts for im-
munoblotting, diluted in sample buffer containing 5% β-
mercaptoethanol, and boiled. Transcriptional assays were
done using Luciferase reporter plasmids. The cells were
harvested for these assays using 20 mM Tris, (pH 7.4) and
0.1% Triton-X 100, and the values obtained were normal-
ized to β-galactosidase activity expressed from a constitu-
tive SV40-driven expression vector and represented as
relative light units (RLU), or in some cases, corrected Lu-
ciferase values for control, reporter alone transfections
were arbitrarily set to 1.0, and fold activation values were
calculated. Bars represent the mean (n = 3) and error bars
represent the standard error of the mean (n = 3).
Co-immunoprecipitation assays
Protein extracts were prepared as described above. Immu-
noprecipitation was performed using the ExactaCruz
kit (Santa Cruz Biotechnology), as per manufacturer’sinstructions. Precipitated proteins were separated by SDS
PAGE and immunoblotting of proteins was performed as
described above.
Chromatin immunoprecipitation (ChIP)
ChIP experiments followed the guidelines set by EZ
ChIP™ (Upsate) with minor modifications. Approxi-
mately 1× 107 C2C12 cells were fixed with 1% formalde-
hyde (Sigma) for 15 minutes at 37°C. Fixing was
quenched by Glycine (Bioshop, Burlington, ON Canada)
at a final concentration of 0.125 M. Cells were collected
in PBS containing phenylmethylsulfonyl fluoride (PMSF)
(Sigma) and protease inhibitor cocktail (Roche, Laval,
Quebec, Canada). Cells were collected at 5000 rpm for 5
minutes at 4°C. Cells were lysed using Wash Buffer I (10
mM HEPES pH 6.5, 0.5 M ethylene glycol tetraacetic
acid (EGTA), 10 mM EDTA, 0.25% Triton X-100, prote-
ase inhibitor cocktail, PMSF) for 5 minutes on ice. Nu-
clei were collected and resuspended in Wash Buffer II
(10 mM HEPES pH 6.5, 0.5 mM EGTA, 1 mM EDTA,
200 mM NaCl, protease inhibitor cocktail, PMSF) for 10
minutes on ice. Nuclei were again collected and then
treated with nuclear lysis buffer (50 mM Tris–HCl pH
8.1, 10 mM EDTA, 1% SDS). Chromatin was sheared
using a Misonix sonicator to produce 500 bp fragments.
Crosslinked sheared chromatin was collected following
a 15-minute spin at maximum speed. Twenty percent
of total chromatin was set aside as input. Sheared
crosslinked chromatin was diluted 1:10 with immuno-
precipitation (IP) dilution buffer (0.01% SDS, 1.1%
Triton-X 100, 1.2 mM EDTA, 16.7 mM Tris–HCl pH
8.1, 167 mM NaCl) and incubated with antibody over-
night at 4°C with rocking. Protein G Dynabeads
(Invitrogen) were blocked with 20 μg salmon sperm
DNA in IP dilution buffer (15 μl of beads + 135 μl IP
dilution buffer + 20 μg salmon sperm DNA per IP)
overnight at 4°C with rocking. We incubated 152 μl of
pre-blocked beads with the IP reaction at 4°C for 1 h.
Dynabead-bound antibody-chromatin complexes were
washed using IP Wash Buffer I (20 mM Tris pH 8.1, 2
mM EDTA, 150 mM NaCl, 1% Triton-X 100, 0.1%
SDS) and II (20 mM Tris pH 8.1, 2 mM EDTA, 500
mM NaCl, 1% Triton X-100, 0.1% SDS), each incu-
bated for 10 minutes at 4°C, and followed with two
washes in Tris-EDTA (TE) buffer at 4°C. Protein-DNA
complexes were freed from Dynabeads through the
addition of elution buffer (0.1 M NaHCO3, 1% SDS)
for 30 minutes at RT. To separate protein from DNA,
samples were treated with 12 μl of 5 M NaCl
(BioShop) at 65°C for 4 h or overnight. Protein was
further degraded by the addition of Proteinase K
(Sigma), EDTA, Tris pH 6.5 for 1 h at 45°C. DNA
samples were then purified using a PCR clean up kit




















































Figure 1 Western blot analysis reveals that Krüppel-like factor 6 (KLF6) and Myocyte enhancer factor 2 (MEF2D) are co-expressed in
C2C12 myoblasts. (a) Myoblasts were cultured in growth medium (10% serum), followed by serum withdrawal (2%) for 144 h and harvested at
24-h time intervals. Cells were then lysed and equal amounts of protein (20 μg) were used for western blot analysis. The levels of the indicated
proteins were assessed by a standard immunoblotting technique using specific primary antibodies for each. Actin was used as a loading control.
(b) Immunocytochemistry reveals that KLF6 and MEF2D are co-localized in the nucleus at the myoblast stage but to a lesser extent in
differentiated myotubes. C2C12 cells were treated as previously described by Salma and McDermott, 2012 [14]. We used 4’,6-diaminidino-2-
phenylindole (DAPI) staining for nuclear staining; green and red were used for MEF2D and KLF6 respectively and were then merged. (c)
Transforming growth factor β (TGFβ) treatment potentiates the KLF6 promoter region through MEF2. KLF6 promoter constructs (pROM6 Luc and
pROM6 ΔMEF2 Luc) were used, and Luciferase activities were analyzed upon serum withdrawal, with and without 2 ng/ml TGFβ treatment
as indicated.
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ChIP-qPCR analysis of the KLF6 promoter was done
using BioRad Sybr Green as per the user manual with a
final primer concentration of 0.5 μM. The antibody used
in ChIP was 5 μg αMEF2 (sc-313X; Santa Cruz Biotech-
nology, Inc.). The equivalent amount of rabbit IgG (12–
370, Millipore) was used as a control in each ChIP.
Sequences of the primers flanking the ME2 site on the
KLF6 promoter were: 5’-CTGCAACGTTGGGCTGTA-3’
and 5’-TTGGAAAGACGTCTCACAGG-3’. Each sample
was run in triplicate and then analyzed using percent
















































Figure 2 Myocyte enhancer factor 2 (MEF2)A/D RNA silencing
reveals that MEF2A/D expression is not required for
endogenous Krüppel-like factor 6 (KLF6) protein expression (a).
In contrast siMEF2D appears to de-repress endogenous KLF6 protein
levels. (b) Chromatin immunoprecipitation analysis of MEF2
recruitment onto the KLF6 promoter revealed no change upon
Transforming growth factor β (TGFβ) treatment.Results and discussion
MEF2D and KLF6 expression and co-localization in the
nucleus in skeletal myoblasts
Since KLF6 was identified in the skeletal muscle tran-
scriptome [15], and has also been shown to be an
MEF2D target gene that is involved in the cell survival
pathway in primary embryonal hippocampal neurons
[14], and since MEF2D is also a crucial regulator of
skeletal myogenesis, we wanted to investigate the role
of KLF6 in skeletal myoblasts. We determined that
KLF6 and MEF2D are indeed both co-expressed in
C2C12 myoblasts, and are co-localized in the nucleus
using western blot analysis and immunocytochemistry
respectively (Figures 1a and 1b). Endogenous expres-
sion of KLF6 is detected in C2C12 myoblasts in growth
conditions and sustained upon serum withdrawal and
throughout the course of myogenic differentiation up
to 120 h. Interestingly, we observed that KLF6 protein
expression is downregulated at 48 h, upregulated at
72 h, downregulated at 96 h and upregulated again
at 120 h in a reproducible manner that is not easily
explainable at this point (Figure 1a). Immunofluores-
cence labeling was conducted to observe the cellular
localization of KLF6 with respect to MEF2D in prolifer-
ating myoblasts and then in differentiated myotubes.
The data indicated strong nuclear localization of both
KLF6 (red) and MEF2D (green) in conjunction with nu-
clear (blue) DAPI staining in myoblasts, and less so in
differentiated myotubes (Figure 1b). Since TGFβ has
also been shown to regulate KLF6 expression, we tested
the effect of TGFβ on previously characterized KLF6
reporter gene constructs (pROM6-Luc and pROM6-
Luc ΔMEF2). Serum was withdrawn 24 h after transfec-
tion and treatment with 2 ng/ml TGFβ for 24 h was
carried out as indicated in the figure. The data illus-
trates a 4-fold increase in transcriptional activity of
pROM6-Luc in response to TGFβ treatment, but no ef-
fect on pROM6-Luc ΔMEF2, indicating that TGFβ reg-
ulates the KLF6 promoter, which requires that the
MEF2 cis element is intact (Figure 1c).MEF2A/D expression is not required for KLF6 protein
expression in skeletal myoblasts
Since we had already observed that TGFβ regulates the
KLF6 promoter through MEF2 we wanted to assess the
effect of MEF2A/D knock down using RNA silencing
(Figure 2a). Although siRNA2 for MEF2A appears to
affect KLF6 expression slightly, this observation did
not indicate a strong and consistent effect. On the
other hand, siMEF2D appears to de-repress KLF6 ex-
pression. Since MEF2D is a potent Histone deacetylase 4
(HDAC4) co-factor, siMEF2D might be preventing the
recruitment of HDAC4 to the promoter and hence de-
repressing KLF6. Contrary to our initial hypothesis,
these data indicate that MEF2 is not necessarily required
for KLF6 expression, or that its requirement is only at
the myoblast stage when the cells are responsive to
TGFβ signaling. To further analyze this observation, we
assessed MEF2 recruitment on the KLF6 promoter with
or without TGFβ treatment (Figure 2b). These data indi-
cate that while MEF2 is indeed recruited to the KLF6
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MEF2 recruitment upon TGFβ treatment compared to
the control, implicating a different mechanism for TGFβ
activation of KLF6.
TGFβ regulates KLF6 through a Smad3-specific pathway
and inhibits skeletal myogenesis through an MEK/ERK-
specific pathway
Since Smad3 is activated in proliferating myoblasts and
is also regulated by TGFβ, we observed that Smad3,
along with MEF2 and KLF6, are co-expressed in skeletal
myoblasts (Figure 3a). To further investigate the effect
of TGFβ on KLF6 we used well-documented pharmaco-
logical inhibitors of the Smad and ERK1/2 Mitogen acti-
vated protein kinase (MAPK) pathways. We tested the
effect of TGFβ on KLF6 protein expression in C2C12
myoblasts in the presence and absence of a Smad3 inhibi-
tor, Sis3 (Figure 3b). The data in Figure 3b reveal that
indeed, TGFβ treatment increases KLF6 protein levels













Figure 3 Western blot analysis revealed that Smad3 and Krüppel-like
Myogenin was used as a protein marker for differentiation and actin was u
Transforming growth factor β (TGFβ) signaling pathway reveals that TGFβ r
MAPK. (b) Western blot analysis indicates that 2 ng/ml TGFβ treatment elev
presence of 5 μM of specific inhibitor of Smad3, Sis3. TGFβ treatment also
expression level, and this effect was not abrogated by Sis3. (c) Western blo
through Smad3 but not ERK1/2 MAPK and that TGFβ treatment repressed
U0126 was used as an inhibitor of the MEK/ERK MAPK pathway, 5 μM Sis3
indicated. Actin was used as a loading control.an indicator of myogenic differentiation. Interestingly,
pharmacological inhibition of Smad3 with 5 μM Sis3 re-
duced TGFβ-induced KLF6 protein expression but had no
effect on myogenin. This indicates that TGFβ regulates
KLF6 and myogenin through two distinct pathways.
Smad2/3 and phospho-Smad2/3 antibodies were used as
positive controls for Sis3 treatment since Sis3 inhibits
Smad3 phosphorylation and hence its translocation into
the nucleus [33]. Since TGFβ also regulates the MEK
stands for MAP kinase, ERK kinase Kinase (MEK)/ERK
(1/2) MAPK pathway we wanted to test the effect of
pharmacological inhibition of that pathway on KLF6
using 10 μM U0126. The data summarized in Figure 3c
confirm that TGFβ induces KLF6 protein expression
while inhibiting myotube formation (using sarcomeric
myosin heavy chain expression as an indicator). In this ex-
periment Smad3 inhibition repressed TGFβ induction of
KLF6 but did not reverse the effects on Myosin heavy chain
(MyHC) (Figure 3c). Strikingly, pharmacological inhibition
of ERK1/2 had no effect on KLF6 levels but instead rescuedDMSO +










factor 6 (KLF6) are co-expressed in C2C12 myoblasts (a).
sed as a loading control. Pharmacological manipulation of the
egulates KLF6 protein expression through Smad3 but not MEK/ERK
ates KLF6 protein expression and that this effect is abrogated in the
inhibited the myogenic differentiation marker, myogenin protein
t analysis revealed that TGFβ treatment enhances KLF6 expression
myogenic differentiation through ERK1/2 MAPK but not Smad3; 10 μM
was used for Smad3 inhibition and 2 ng/ml TGFβ were all used as
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the idea that TGFβ regulates KLF6 and myogenic differenti-
ation through Smad3 and ERK1/2 distinctively.
TGFβ induces cell proliferation in C2C12 myoblasts
through KLF6
Since TGFβ represses skeletal myogenesis by retaining
cells in a proliferative state, we wanted to test the effect of
KLF6 mRNA silencing using siRNA-mediated gene silen-
cing. siRNA3 was chosen as the most efficient in depleting






























MTT Cell Proliferation 
Assay
TGFβ (2 ng/ml)                  +          +           
siKLF6 (3) +          +      
c
Figure 4 Krüppel-like factor 6 (KLF6) RNA silencing reveals that KLF6
siRNA3, which was used in subsequent experiments (a). (b) KLF6 RNA
(ii) enhanced MCK Luciferase activity and, (iii) reduced transforming growth
measured using the MTT cell proliferation assay kit. The number of prolifera
treatment doubled the number of proliferating cells and this effect was rep
presented, in which TGFβ/Extracellular signal regulated kinase (ERK) signalin
regulates KLF6 gene expression and myoblast proliferation.silencing resulted in increased MyoD and myogenin
protein expression (Figure 4b, upper panel) and this
corresponded with a 2.5-fold increase in muscle creatine
kinase (MCK) promoter (Figure 4b, lower panel). Further-
more, an MTT cell proliferation assay was performed, and
the data showed that at 24 h, 2 ng/ml TGFβ treatment
doubles the number of proliferating cells (Figure 4c).
This effect is largely negated following KLF6 gene silen-
cing, thus implicating KLF6 in the proliferative
response to TGFβ signaling. In support of this, siKLF6
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protein expression was successfully repressed, particularly by
silencing resulted in (i) increased MyoD and myogenin protein levels,
factor β (TGFβ) induced cell proliferation. (c) Cell proliferation was
ting cells is directly proportional to the absorbance at 570 nm. TGFβ
ressed with KLF6 silencing. (d) A schematic summary of the data
g represses myogenic differentiation while TGFβ/Smad signaling
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myoblasts (Figure 4c).
Conclusions
In this study we report a novel role for KLF6 in skeletal
myoblasts. Based on our data we propose that KLF6 is a
downstream effector of the TGFβ/Smad3 pathway that
regulates cell proliferation in skeletal myoblasts. We
identify Smad3 as a key regulator of KLF6 expression,
through TGFβ. In addition we were able to functionally
distinguish between the TGFβ/Smad and TGFβ/MAPK
pathways in that TGFβ inhibits skeletal myogenesis
through the MEK/ERK (1/2) MAPK pathway and con-
comitantly enhances cell proliferation through Smad3-
mediated induction of KLF6 expression. Our findings
are summarized in Figure 4d. Many myopathies and
muscle loss disorders have been linked with increased
TGFβ signaling [34] and hence, our findings identify
KLF6 as a potential therapeutic target for such patho-
logical conditions, as well as for cancers, such as embry-
onal rhabdomyosarcoma, where TGFβ promotes cell
proliferation [35].
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